TG Therapeutics (TGTX)
Commercializes BRIUMVI while developing B-cell therapies for immune-mediated diseases.
$55.92
vs last close−2.19 (−3.77%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 73.56% | 112.59M shares | |
|---|---|---|---|
| 463 holders · as of Jun 30, 2026 | |||
| Insiders | 7.54% | 11.54M shares | |
| 7 holders · as of Sep 14, 2026 | |||
| Strategic holders | 8.25% | 12.63M shares | |
| 1 holder · as of Sep 11, 2020 | |||
| Other | 10.65% | 16.31M shares | |
| remainder | |||
153.07M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
463 holders · 112.59M shares · 107 new positions · 255 increased · 127 reduced · 39 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 22.05M | 14.41% | −202.9K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.96M | 5.20% | −310.7K | Aug 13, 2026 |
| State Street Corp | 7.79M | 5.09% | −863.3K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 6.15M | 4.02% | −453.9K | Aug 13, 2026 |
| Geode Capital Management, LLC | 3.64M | 2.38% | +142.3K | Aug 12, 2026 |
| D. E. Shaw & Co., Inc. | 3.40M | 2.22% | +2.81M | Aug 14, 2026 |
| Soleus Capital Management, L.P. | 2.93M | 1.91% | −1.10M | Aug 11, 2026 |
| Price T Rowe Associates Inc /MD/ | 2.77M | 1.81% | +2.13M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.80% | 20.13M | 13G | Apr 30, 2025 |
| Vanguard Portfolio Management | 5.26% | 8.40M | 13G | Apr 29, 2026 |
| State Street Corporation | 5.10% | 8.10M | 13G | Nov 10, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 10, 2026 | Laurence N. Charneydirector | Sale | 5,000 | $54.96 | 168,640 |
| Nov 24, 2025 | Yann Echelarddirector | Sale | 5,000 | $32.57 | 223,816 |
House and Senate disclosures
Not reported.